Stock Research for SPHS


Featured Broker: Ally Invest

Get the due diligence for another stock.


SPHS Stock Chart & Research Data

The SPHS chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the SPHS chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


SPHS Due diligence Resources & Stock Charts

The SPHS stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View SPHS Detailed Price Forecast - CNN Money CNN View SPHS Detailed Summary - Google Finance
Yahoo View SPHS Detailed Summary - Yahoo! Finance Zacks View SPHS Stock Research & Analysis -

Stock Analysis

TradeIdeas View SPHS Trends & Analysis - Trade-Ideas Barrons View SPHS Major Holders - Barrons
NASDAQ View SPHS Call Transcripts - NASDAQ Seeking View SPHS Breaking News & Analysis - Seeking Alpha
Spotlight View SPHS Annual Report - OTC Report View SPHS OTC Short Report -
TradeKing View SPHS Fundamentals - TradeKing Charts View SPHS SEC Filings - Bar Chart
WSJ View Historical Prices for SPHS - The WSJ Morningstar View Performance/Total Return for SPHS - Morningstar
MarketWatch View the Analyst Estimates for SPHS - MarketWatch CNBC View the Earnings History for SPHS - CNBC
StockMarketWatch View the SPHS Earnings - StockMarketWatch MacroAxis View SPHS Buy or Sell Recommendations - MacroAxis
Bullish View the SPHS Bullish Patterns - American Bulls Short Pains View SPHS Short Pain Metrics -

Social Media Mentions

StockTwits View SPHS Stock Mentions - StockTwits PennyStocks View SPHS Stock Mentions - PennyStockTweets
Twitter View SPHS Stock Mentions - Twitter Invest Hub View SPHS Investment Forum News - Investor Hub
Yahoo View SPHS Stock Mentions - Yahoo! Message Board Seeking Alpha View SPHS Stock Mentions - Seeking Alpha

Financial & Transaction Holdings

SECform4 View Insider Transactions for SPHS - Insider Cow View Insider Transactions for SPHS - Insider Cow
CNBC View SPHS Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for SPHS - OTC Markets
Yahoo View Insider Transactions for SPHS - Yahoo! Finance NASDAQ View Institutional Holdings for SPHS - NASDAQ

Stock Charts

FinViz View SPHS Stock Insight & Charts - StockCharts View SPHS Investment Charts -
BarChart View SPHS Stock Overview & Charts - BarChart Trading View View SPHS User Generated Charts - Trading View

Latest Financial News for SPHS

Sophiris Bio Reports Fourth Quarter 2018 and Year-end Financial Results and Recent Corporate Highlights
Posted on Wednesday March 13, 2019

SAN DIEGO and VANCOUVER, British Columbia, March 13, 2019 /PRNewswire/ -- Sophiris Bio Inc. (SPHS) (the "Company," "We" or "Sophiris"), a biopharmaceutical company developing topsalysin (PRX302), a first-in-class, pore-forming protein, in late-stage clinical trials for the treatment of patients with urological diseases, today reported financial results for the fourth quarter and full year 2018 and recent corporate highlights. "During the past year, Sophiris has made important progress in determining the ideal method for topsalysin administration as a focal treatment for localized prostate cancer," said Randall E. Woods, president and CEO of Sophiris. "The Phase 2b study provided a compelling look at this potential, showing that a single administration of topsalysin led to a clinical response in 27% of patients, including a complete ablation of tumor in 16% of patients.

SPHS: Ready to Move Topsalysin into Phase 3 for Localized Clinically Significant Prostate Cancer…
Posted on Wednesday December 19, 2018

A total of 38 patients received a single administration of topsalysin to treat a clinically significant tumor, which was defined for this study as either a Gleason score of 6 (pattern 3 + 3) and greater than or equal to 6 mm maximum cancer core length (MMCL), or a Gleason score of 7 (pattern 3 + 4) and less than or equal to 10 mm MCCL. Ten patients received a second administration of topsalysin due to having a partial response to the first treatment, however their lesions were still clinically significant.

Sophiris Bio Provides Updates on Phase 2b Localized Prostate Cancer Trial
Posted on Monday December 17, 2018

SAN DIEGO and VANCOUVER, British Columbia, Dec. 17, 2018 /PRNewswire/ -- Sophiris Bio Inc. (SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company studying topsalysin (PRX302), a first-in-class, pore-forming protein, in late-stage clinical trials for the treatment of patients with urological diseases, today provides an update from its Phase 2b study of topsalysin for localized prostate cancer, including top-line safety and biopsy results from the patients who received a second administration of study drug, which appeared to be safe and generally well-tolerated. Additional benefit was not observed on targeted biopsy six months after re-treatment with a second administration of topsalysin. As previously stated, a total of 27% of patients (10/37) demonstrated a clinical response six months following a single administration of topsalysin.

Does Sophiris Bio Inc (FRA:BFF1) Have A Volatile Share Price?
Posted on Thursday December 06, 2018

If you own shares in Sophiris Bio Inc (FRA:BFF1) then it's worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a measure Read More...

Stock Market & Investing Books

Enter a stock symbol to view the stock details.